Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy
Open Access
- 14 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2) , e14678
Abstract
The failure of cytotoxic cancer regimens to cure the most drug-resistant, well-differentiated solid tumors has been attributed to the heterogeneity of cell types that differ in their capacities for growth, differentiation, and metastases. We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO). Subsequently, we evaluated the increased efficacy of chemotherapy combined with LB1. The effect of LB1 and temozolomide (TMZ), a standard chemotherapeutic agent that alone only transiently suppressed the growth and regression of metastatic PHEO, was evaluated in vitro on a single PHEO cell line and in vivo on mouse model of metastatic PHEO. In the present study, we show that metastatic PHEO, for which there is currently no cure, can be eliminated by combining LB1, thereby inhibiting PP2A, with TMZ. This new treatment approach resulted in long term, disease-free survival of up to 40% of animals bearing multiple intrahepatic metastases, a disease state that the majority of patients die from. Inhibition of PP2A was associated with prevention of G1/S phase arrest by p53 and of mitotic arrest mediated by polo-like kinase 1 (Plk-1). The elimination of DNA damage-induced defense mechanisms, through transient pharmacologic inhibition of PP2A, is proposed as a new approach for enhancing the efficacy of non-specific cancer chemotherapy regimens against a broad spectrum of low growth fraction tumors very commonly resistant to cytotoxic drugs.Keywords
This publication has 34 references indexed in Scilit:
- Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitorsEndocrine-Related Cancer, 2010
- Revealing Global Regulatory Perturbations across Human CancersMolecular Cell, 2009
- Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapyEuropean Journal of Pharmacology, 2009
- Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteomeCell Cycle, 2009
- The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with ParagangliomasThe Journal of Clinical Endocrinology & Metabolism, 2009
- Clinical Utility of Temozolomide in the Treatment of Malignant Paraganglioma: A Preliminary ReportHormone and Metabolic Research, 2009
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine TumorsJournal of Clinical Oncology, 2006
- Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout miceCell and tissue research, 2000
- Polo-like kinase-1 is a target of the DNA damage checkpointNature Cell Biology, 2000
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000